Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Consultations and record cards
Lab Invest (2018) 98(5):62939
In type 2 diabetes, it often outperforms older therapies on both blood sugar and weight, which is why it is quickly becoming a backbone drug in highrisk metabolic patients. Better glycemic control cuts the risk of microvascular complications (eye disease, kidney damage, nerve damage) and macrovascular events (heart attack, stroke) over time. Fewer amputations, fewer cases of kidney failure, and fewer disabling strokes are core drivers of lost lifeyears and compressed healthspan that tirzepatide helps push back against. 3
Tirzepatide Tirzepatide, also known by the brand names Mounjaro and Zepbound, is an FDA-approved dual-action GLP-1/GIP receptor agonist made by Eli Lilly
Real-world impact of GLP-1 receptor agonists on endoscopic patient outcomes in an ambulatory setting: a retrospective study at a large tertiary center
The SURMOUNT-4 maintenance trial showed similar patterns for tirzepatide
